Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

[1] Stamler J(1993)Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434-444

[2] Vaccaro O(2003)B-Type natriuretic peptide in cardiovascular disease Lancet 362 316-322

[3] Neaton JD(2001)Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction Clin Chim Acta 310 193-197

[4] Wentworth D(1993)Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction Lancet 341 1109-1113

[5] de Lemos JA(2002)Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) Circulation 106 2454-2458

[6] McGuire DK(2002)Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure J Am Coll Cardiol 39 1623-1629

[7] Drazner MH(2000)Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 1126-1130

[8] Hammerer-Lercher A(1999)Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy Am Heart J 138 1126-1132

[9] Neubauer E(2003)Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383-393

[10] Muller S(2003)Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay Clin Chim Acta 338 107-115

[1] Stamler J(1993)Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434-444

[2] Vaccaro O(2003)B-Type natriuretic peptide in cardiovascular disease Lancet 362 316-322

[3] Neaton JD(2001)Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction Clin Chim Acta 310 193-197

[4] Wentworth D(1993)Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction Lancet 341 1109-1113

[5] de Lemos JA(2002)Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) Circulation 106 2454-2458

[6] McGuire DK(2002)Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure J Am Coll Cardiol 39 1623-1629

[7] Drazner MH(2000)Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 1126-1130

[8] Hammerer-Lercher A(1999)Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy Am Heart J 138 1126-1132

[9] Neubauer E(2003)Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383-393

[10] Muller S(2003)Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay Clin Chim Acta 338 107-115